

ABSTRACT OF THE DISCLOSURE

5

The invention also relates to the use of of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to regulation of expression of at least one gene in a cell, e.g., *Cyr61* gene.

10

[illegible]